1,721,048 research outputs found
Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease.
No full textINTRODUCTION:
To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease.
METHODS:
Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up.
RESULTS:
Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm(2) (mean±SD) at baseline to 4.23±3.31 mm(2) at the end of the follow-up.
CONCLUSIONS:
Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma
No full textPURPOSE: To evaluate photodynamic therapy (PDT) with verteporfin for iris and angle neovascularization in eyes with neovascular glaucoma.DESIGN: Interventional case series.METHODS: A prospective, noncomparative case series included four patients (four eyes) with neovascular glaucoma. PDT was performed following the parameters of treatment of age-related macular degeneration with photodynamic therapy Study Group (TAP). The laser was directed at the anterior chamber angle and iris surface using a Goldmann three-mirror contact lens. Iris and angle neovascularization were quantified using the number of clock hours involved. Outcome measures were obliteration of neovascularization and decrease of intraocular pressure (IOP).RESULTS: One week after PDT, we registered complete obliteration of angle neovascularization and partial occlusion of iris neovascularization. Subsequent reopening of angle neovascularization was detectable at 1 month. Intraocular pressure diminished considerably after 1 week, with a subsequent tendency toward stabilization.CONCLUSIONS: Photodynamic therapy can be used safely and effectively in the early phases of neovascular glaucoma to achieve angle neovascularization obliteration and IOP reduction
One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
No full textFundus autofluorescence in subfoveal choroidal neovascularisation secondary to Pathological myopia
No full textTemporary Intraocular Pressure Lowering by Photodynamic Therapy in Pseudoexfoliation Glaucoma
No full textBACKGROUND AND OBJECTIVE: The aim of the study was to ascertain whether photodynamic therapy (PDT) with verteporfin is able to reduce the blood-aqueous barrier impairment in eyes affected by pseudoexfoliative glaucoma (PESG) with consequent intraocular pressure (IOP) lowering. PATIENTS AND METHODS: Five patients with poorly controlled PESG were selected. The laser energy was directed to the anterior chamber angle and the iris surface by means of a Goldmann lens. RESULTS: IOP reduction was registered 1 month after PDT and lasted 3 months, reaching the values registered before PDT after that. Iris fluorescein angiography 1 week and 1 month after PDT showed reduced dye leakage, but the same amount of dye leakage visible before PDT was detectable 3 months later. CONCLUSION: PDT can reduce the breakdown of the blood-aqueous barrier and can lower the IOP temporarily in eyes affected by PESG. Further studies are needed to analyze the biochemical changes after PDT in aqueous humor
Fundus autofluorescence in subfoveal choroidal neovascularisation secondary to Pathological Myopia
No full textAIM: To describe the fundus autofluorescence (FAF) characteristics of choroidal neovascularisation (CNV) associated with pathological myopia (PM), and their modification after photodynamic therapy (PDT).DESIGN: Open-label, prospective, interventional case series.METHODS: Forty-two patients affected by subfoveal CNV in PM underwent PDT with a 24-month follow-up. Each patient underwent an ophthalmological examination every 3 months, including FAF and fluorescein angiography. FAF distribution was qualitatively evaluated at the CNV site, around the CNV and outside the area affected by CNV.RESULTS: CNV at baseline showed a high FAF signal with uniform distribution, or with some spots of low FAF internally, in 64% and 36% of cases, respectively. At the 3-month control after PDT, the CNV retained the same response, but a round halo of increased signal extending beyond the site of the PDT application was detectable around the CNV. At the end of the follow-up, a high or a low FAF signal was detected in 40% and 60% of cases, respectively.CONCLUSION: CNV secondary to PM shows a specific, high signal, FAF pattern. A round halo of increased FAF signal surrounding the CNV was detectable after PDT application, whereas a FAF signal progressive reduction was visible at and around the CNV site from the sixth month. A high FAF signal at the CNV site is associated with an improved visual acuity outcome at the 2-year follow-up. Further studies to correlate the morphological and functional features are advisable, especially by means of microperimetric analyses and with a longer-term follow-up
- …
